$101.9 B

GSK.L Mkt cap, 11-Jul-2018

£7.2 B

GlaxoSmithKline Revenue Q1, 2018
GlaxoSmithKline Gross profit (Q1, 2018)4.8 B
GlaxoSmithKline Gross profit margin (Q1, 2018), %66.9%
GlaxoSmithKline Net income (Q1, 2018)759 M
GlaxoSmithKline EBIT (Q1, 2018)1.2 B
GlaxoSmithKline Cash, 31-Mar-20184 B
GlaxoSmithKline EV115.4 B

GlaxoSmithKline Revenue

GlaxoSmithKline revenue was £30.19 b in FY, 2017 which is a 8.2% year over year increase from the previous period.

Embed Graph

GlaxoSmithKline Revenue Breakdown

Embed Graph

GlaxoSmithKline revenue breakdown by business segment: 25.7% from Consumer Healthcare, 17.1% from Vaccines and 57.2% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 59.6% from International, 37.3% from US and 3.1% from Other

GlaxoSmithKline Income Statement

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Revenue

18.1 b20.5 b21.2 b21.4 b20.4 b21.7 b23.2 b22.7 b26.5 b27.9 b30.2 b

Revenue growth, %

17%8%

Cost of goods sold

4 b4.7 b4.6 b4.5 b4.3 b4.8 b5 b5.3 b8.6 b9.3 b10.3 b

Gross profit

14.1 b15.8 b16.6 b16.9 b16 b16.9 b18.2 b17.4 b17.9 b18.6 b19.8 b

Gross profit Margin, %

78%77%78%79%79%78%78%77%68%67%66%

R&D expense

3.6 b4.5 b

General and administrative expense

9.4 b9.7 b

Operating expense total

9.4 b11 b11.1 b10.5 b10 b10 b10.4 b9.8 b10.9 b16 b15.8 b

EBITDA

8.7 b9.3 b

EBITDA margin, %

38%35%

EBIT

4.7 b4.7 b5.6 b6.4 b6.1 b6.9 b7.8 b7.6 b7 b2.6 b4.1 b

EBIT margin, %

26%23%26%30%30%32%34%33%27%9%14%

Interest expense

736 m734 m

Interest income

72 m65 m

Pre tax profit

6 b4.5 b5.5 b6.3 b6.1 b6.7 b7.8 b7.5 b6.6 b1.9 b3.5 b

Income tax expense

(1.7 b)(1.3 b)(1.5 b)(1.7 b)(1.7 b)(1.9 b)(2.3 b)(2.1 b)(1 b)877 m1.4 b

Net Income

4.3 b3.2 b4 b4.6 b4.4 b4.8 b5.5 b5.3 b5.6 b1.1 b2.2 b

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

7.4 b7.3 b7.8 b7.2 b

Cost of goods sold

2.5 b2.6 b2.7 b2.4 b

Gross profit

4.9 b4.7 b5.2 b4.8 b

Gross profit Margin, %

66%64%66%67%

R&D expense

960 m1.3 b1 b904 m

General and administrative expense

2.5 b2.4 b2.3 b2.3 b

Operating expense total

3.2 b4.7 b3.3 b3.6 b

EBIT

1.7 b(20 m)1.9 b1.2 b

EBIT margin, %

23%0%24%17%

Interest expense

194 m192 m194 m162 m

Interest income

21 m15 m13 m20 m

Pre tax profit

1.6 b(178 m)1.7 b1.1 b

Income tax expense

327 m(92 m)316 m348 m

Net Income

1.2 b(86 m)1.4 b759 m

GlaxoSmithKline Balance Sheet

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Cash

1.3 b716 m1.1 b962 m1.2 b4.2 b2 b3.4 b5.5 b4.9 b3.8 b

Accounts Receivable

3.3 b3.6 b3.5 b3.7 b3.8 b4.4 b4.4 b4.6 b4 b6 b6 b

Inventories

2.3 b2.1 b2.1 b2.1 b2.2 b2.2 b2.4 b3.1 b3.9 b5.1 b5.6 b

Current Assets

11.3 b10 b10.7 b12.6 b13.6 b13.2 b11 b13.6 b15.2 b16.7 b15.9 b

PP&E

9.2 b10.1 b9.8 b9.5 b6.8 b9.9 b10.5 b7.8 b8.9 b10.8 b10.9 b

Goodwill

6 b5.7 b

Total Assets

21.6 b21.9 b22.3 b24 b22.6 b27.2 b25.6 b31 b42.1 b59.1 b56.4 b

Accounts Payable

812 m760 m715 m686 m707 m819 m865 m931 m2.7 b12 b21 b

Short-term debt

4.1 b2.8 b

Current Liabilities

9.1 b9.4 b8.8 b8.6 b8.7 b9.5 b7.3 b10.3 b13.7 b19 b26.6 b

Long-term debt

14.7 b14.3 b

Non-Current Liabilities

4.8 b5 b6.9 b7.7 b7.9 b10.4 b8.9 b11.1 b21.4 b35.1 b26.3 b

Total Debt

191 m230 m193 m155 m112 m1.1 b676 m3.5 b2.8 b18.8 b17.1 b

Total Liabilities

13.9 b14.4 b15.7 b16.3 b16.7 b19.9 b16.2 b21.4 b35.1 b54.1 b52.9 b

Common Stock

1.3 b1.3 b

Additional Paid-in Capital

1.6 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.3 b3 b3 b

Retained Earnings

4.2 b703 m1.6 b2.1 b1.9 b2.3 b2.8 b2.4 b1.9 b(5.4 b)(6.5 b)

Total Equity

7.7 b7.5 b6.6 b7.7 b5.9 b7.3 b9.4 b9.6 b7 b5 b3.5 b

Debt to Equity Ratio

0 x0 x0 x0 x0 x0.2 x0.1 x0.4 x0.4 x3.8 x4.9 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0.3 x0.3 x

Financial Leverage

2.8 x2.9 x3.4 x3.1 x3.8 x3.7 x2.7 x3.2 x6 x11.9 x16.2 x

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

4.5 b4 b4.7 b4 b

Accounts Receivable

6.2 b6.2 b6.5 b6.1 b

Inventories

5.4 b5.7 b5.7 b5.7 b

Current Assets

16.8 b16.4 b17.7 b16.4 b

PP&E

10.8 b10.7 b10.6 b10.7 b

Goodwill

6 b5.9 b5.8 b5.6 b

Total Assets

59.2 b58.2 b5.9 b56.2 b

Accounts Payable

12 b19.6 b19.8 b21.1 b

Short-term debt

3.7 b6.6 b4.7 b3.4 b

Current Liabilities

18.8 b28.8 b27.4 b26.9 b

Long-term debt

14.6 b12.3 b14.3 b14 b

Non-Current Liabilities

34.9 b25 b26.5 b25.6 b

Total Debt

18.3 b18.9 b19 b17.5 b

Total Liabilities

53.6 b53.8 b54 b52.6 b

Common Stock

1.3 b1.3 b1.3 b1.3 b

Additional Paid-in Capital

3 b3 b3 b3 b

Retained Earnings

(4.9 b)(5.9 b)(5.3 b)(6.4 b)

Total Equity

5.6 b4.4 b4.8 b3.6 b

Debt to Equity Ratio

4.3 x3.9 x4.9 x

Debt to Assets Ratio

0.3 x3.2 x0.3 x

Financial Leverage

10.6 x13.2 x1.2 x15.6 x

GlaxoSmithKline Cash Flow

Annual

GBPFY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2016FY, 2017

Net Income

4.3 b3.2 b4 b4.6 b4.4 b4.8 b5.5 b5.3 b5.6 b1.1 b2.2 b

Depreciation and Amortization

2 b2.9 b

Accounts Receivable

(188 m)(287 m)

Inventories

70 m(461 m)

Accounts Payable

96 m11 m

Cash From Operating Activities

5.4 b6.5 b7.3 b7 b6.5 b6 b4.4 b6.2 b7.2 b6.5 b6.9 b

Purchases of PP&E

(1.5 b)(1.5 b)

Cash From Investing Activities

(1.3 b)(1.4 b)

Short-term Borrowings

148 m(3.2 b)

Long-term Borrowings

(18 m)(23 m)

Dividends Paid

56 m2.4 b2.4 b2.4 b2.4 b2.4 b2.6 b2.8 b3.7 b(4.9 b)(3.9 b)

Cash From Financing Activities

(546 m)(1.4 b)(1.6 b)(276 m)(454 m)(2.9 b)(4.8 b)(1.7 b)(6.3 b)(6.4 b)(6.4 b)

Net Change in Cash

822 m612 m405 m27 m257 m1.4 b2 b1.4 b1.5 b(1.2 b)(905 m)

Interest Paid

(732 m)(781 m)

Income Taxes Paid

(1.6 b)(1.3 b)

Quarterly

GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

1.2 b1.1 b2.5 b759 m

Cash From Operating Activities

1.1 b2.2 b4 b863 m

Purchases of PP&E

(260 m)(639 m)(1 b)(258 m)

Cash From Investing Activities

(199 m)(646 m)(1.1 b)(371 m)

Short-term Borrowings

(528 m)386 m(1.4 b)701 m

Long-term Borrowings

(3 m)(13 m)(18 m)(7 m)

Dividends Paid

(925 m)(2 b)(3 b)(929 m)

Cash From Financing Activities

(1.5 b)(2.5 b)(3.1 b)(283 m)

Net Change in Cash

(564 m)(968 m)(182 m)209 m

Income Taxes Paid

(206 m)(557 m)(893 m)(198 m)

GlaxoSmithKline Ratios

GBPY, 2018

EV/EBIT

93 x

EV/CFO

133.7 x

Debt/Equity

4.9 x

Debt/Assets

0.3 x

Financial Leverage

15.6 x
Report incorrect company information

GlaxoSmithKline Operating Metrics

GlaxoSmithKline's Unique Visitors was reported to be 1.8 m in FY, 2015.
FY, 2014FY, 2015FY, 2016FY, 2017

Consumer Healthcare Products Produced

6.20 b

Countries

100 100 100

Manufacturing Facilities

57 54 87

Markets

150 150 150

New Product Launches

50 40 30

Partners

1.50 k1.50 k2 k

Unique Visitors

1.80 m

Vaccine Doses Delivered per Day

2 m

Vaccines

798 m

Volume of Medicines Produced

1.90 b
Report incorrect company information